Video

Evolving Treatment Paradigm of Resectable CSCC

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

Related Videos
Peter Forsyth, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Richard Kim, MD, Moffitt Cancer Center
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
RP1 Plus Nivolumab in Advanced Melanoma
November 22nd 2024

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Blessy Mathew Jacob, MD; Ana Van Der Wall, MD; Vance M. Wright-Browne, MD
February 8th 2024

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

Lung Cancer
November 11th 2024

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors